
THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History Ma

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Note: Use of Direct Oral Anticoagulants (DOAC) [apixaban, rivaroxaban, edoxaban, dabigartan] is not recommended for prevention of VTE in cancer patients as safety and efficacy data are lacking



³ See Appendix B for Relative Contraindications to Pharmacological Options for VTE Prophylaxis

⁴ See Appendix C for Pharmacological Options for VTE Prophylaxis

⁵ See Appendix D for Mechanical Options for VTE Prophylaxis

Copyright 2018 The University of Texas MD Anderson Cancer Center

Page 1 of 5

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History⁸ Venous Thromboembolism (VTE) Prophylaxis for Hospitalized Adult Patients

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

APPENDIX A: VTE Risk Factors

- Active cancer (or suspicion of cancer)
- Age 60 years or older
- Prior VTE
- Advanced stage of cancer
- Medical comorbidities (infection, renal disease, pulmonary disease, congestive heart failure, arterial thromboembolism)
- Familial and/or acquired hypercoagulability
- Major surgery (abdominal, pelvic, orthopedic surgery)
- Central venous catheter/IV catheter
- Chemotherapy (especially bevacizumab, thalidomide/lenalidomide plus high-dose dexamethasone)

- Exogenous estrogen compounds (hormone replacement, contraceptives, tamoxifen/raloxifene, diethylstilbestrol)
- Erythropoietin stimulating agents
- Poor performance status
- Nephrotic syndrome
- Major trauma
- Spinal cord injury
- Smoking
- Obesity (BMI greater than 30 kg/m²)
- Pregnancy

APPENDIX B: Relative Contraindications to Pharmacological Options for VTE Prophylaxis

- Active bleeding (cerebral, GI, GU)
- Thrombocytopenia (platelets less than 50 K/microliter)
- Anticipated thrombocytopenia
- Heparin-induced thrombocytopenia (HIT)
- Recent major surgery at high risk of bleeding
- Recent CNS bleed within 72 hours
- Neurosurgery within 72 hours
- Intracranial or spinal lesion at high risk of bleeding
- Recent GI bleed
- Underlying coagulopathy
- Patient on protocol that prohibits anticoagulation
- End of life care
- Uncontrolled hypertension (greater than 200 mmHg/120 mmHg)

Page 2 of 5

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History* Venous Thromboembolism (VTE) Prophylaxis for Hospitalized Adult Patients

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

APPENDIX C: Pharmacological Options for VTE Prophylaxis

- 1. Unfractionated heparin (drug of choice in renal failure or dialysis) 5,000 units subcutaneously every 8 hours or 7,500 units subcutaneously every 8 hours for BMI greater than or equal to 40 kg/m²
- 2. Enoxaparin 40 mg subcutaneously every 24 hours or 40 mg subcutaneously every 12 hours for BMI greater than or equal to 40 kg/m²
- 3. Enoxaparin 30 mg subcutaneously every 12 hours
- 4. Enoxaparin 30 mg subcutaneously every 24 hours (creatinine clearance (CrCl) stable but between 20-30 mL/minute)
- For CrCl less than 20 mL/minute or on dialysis, unfractionated heparin is preferred
- 5. Dalteparin 5,000 units subcutaneously every 24 hours
- 6. For patients intolerant to heparin products or for those who prefer to avoid pork products: fondaparinux 2.5 mg subcutaneously every 24 hours (contraindicated if total body weight less than 50 kg and/or CrCl less than 30 mL/minute)

Note: Apixaban 2.5 mg by mouth every 12 hours or rivaroxaban 10 mg by mouth every 24 hours is recommended only for cancer patients with a history of HIT or when a patient prefers to avoid pork-derived products.

APPENDIX D: Mechanical Options for VTE Prophylaxis

- Sequential compression devices (SCDs)
- Graduated compression stockings (TED hoses)

Page 3 of 5

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History^a Venous Thromboembolism (VTE) Prophylaxis for Hospitalized Adult Patients

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Aloia, T. A., Geerts, W. H., Clary, B. M., Day, R. W., Hemming, A. W., D'Albuquerque, L. C., ... & Toogood, G. J. (2016). Venous thromboembolism prophylaxis in liver surgery. *Journal of Gastrointestinal Surgery*, 20(1), 221-229.
- Gould, M. K., Garcia, D. A., Wren, S. M., Karanicolas, P. J., Arcelus, J. I., Heit, J. A., & Samama, C. M. (2012). Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. *CHEST Journal*, 141(2_suppl), e227S-e277S.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Venous Thromboembolic Disease Version 2.2013. Retrieved from http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Cancer-Associated Venous Thromboembolic Disease Version 1.2018. Retrieved from http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf
- Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., ... & Mendelson, D. (2007). American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. *Journal of clinical oncology*, 25(34), 5490-5505.
- Leonardi, M. J., McGory, M. L., & Ko, C. Y. (2006). The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: a systematic review of 33 randomized controlled trials. *Archives of Surgery*, 141(8), 790-799.
- Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008). Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest journal*, 133(6_suppl), 381S-453S.
- Scholten, D. J., Hoedema, R. M., & Scholten, S. E. (2002). A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. *Obesity surgery*, 12(1), 19-24.

Page 4 of 5

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History^a Venous Thromboembolism (VTE) Prophylaxis for Hospitalized Adult Patients

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice consensus algorithm is based on majority expert opinion of the VTE workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Thomas A. Aloia, MD (Surgical Oncology) Carmen Escalante, MD (General Internal Medicine) Josiah Halm, MD (General Internal Medicine) Shonice R.Holdman, MBA* Steven Huang, MD (Interventional Radiology) Michael Kroll, MD (Benign Hemagology)^T Claire Marten, PharmD (Pharmacy Clinical Programs) Deborah A. McCue, PharmD (Pharmacy Clinical Programs) Amy Pai, PharmD* Ali Zalpour, PharmD (Pharmacy Clinical Programs)

[†]Core Development Team Lead
[•]Clinical Effectiveness Development Team

Page 5 of 5